Sign up to access all valuation multiples
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
1993
8.2K+
LTM Revenue $429M
LTM EBITDA $117M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Syngene International has a last 12-month revenue (LTM) of $429M and a last 12-month EBITDA of $117M.
In the most recent fiscal year, Syngene International achieved revenue of $402M and an EBITDA of $131M.
Syngene International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Syngene International valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $429M | XXX | $402M | XXX | XXX | XXX |
| Gross Profit | $318M | XXX | $294M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $117M | XXX | $131M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $71.7M | XXX | $70.3M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $52.3M | XXX | $56.8M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Syngene International's stock price is INR 625 (or $7).
Syngene International has current market cap of INR 251B (or $2.9B), and EV of INR 243B (or $2.8B).
See Syngene International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.9B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Syngene International has market cap of $2.9B and EV of $2.8B.
Syngene International's trades at 7.0x EV/Revenue multiple, and 21.5x EV/EBITDA.
Equity research analysts estimate Syngene International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Syngene International has a P/E ratio of 55.1x.
See valuation multiples for Syngene International and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 23.7x | XXX | 21.5x | XXX | XXX | XXX |
| EV/EBIT | 38.8x | XXX | 39.1x | XXX | XXX | XXX |
| EV/Gross Profit | 8.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 55.1x | XXX | 50.3x | XXX | XXX | XXX |
| EV/FCF | 87.3x | XXX | 56.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSyngene International's last 12 month revenue growth is 11%
Syngene International's revenue per employee in the last FY averaged $49K, while opex per employee averaged $27K for the same period.
Syngene International's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Syngene International's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Syngene International and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $49K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Syngene International acquired XXX companies to date.
Last acquisition by Syngene International was XXXXXXXX, XXXXX XXXXX XXXXXX . Syngene International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Syngene International founded? | Syngene International was founded in 1993. |
| Where is Syngene International headquartered? | Syngene International is headquartered in India. |
| How many employees does Syngene International have? | As of today, Syngene International has 8.2K+ employees. |
| Who is the CEO of Syngene International? | Syngene International's CEO is Mr. Peter Bains. |
| Is Syngene International publicy listed? | Yes, Syngene International is a public company listed on BOM. |
| What is the stock symbol of Syngene International? | Syngene International trades under 539268 ticker. |
| When did Syngene International go public? | Syngene International went public in 2015. |
| Who are competitors of Syngene International? | Similar companies to Syngene International include e.g. Jubilant Pharmova, Biocon, Dishman Carbogen Amics, Cohance Lifesciences. |
| What is the current market cap of Syngene International? | Syngene International's current market cap is $2.9B |
| What is the current revenue of Syngene International? | Syngene International's last 12 months revenue is $429M. |
| What is the current revenue growth of Syngene International? | Syngene International revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Syngene International? | Current revenue multiple of Syngene International is 6.5x. |
| Is Syngene International profitable? | Yes, Syngene International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Syngene International? | Syngene International's last 12 months EBITDA is $117M. |
| What is Syngene International's EBITDA margin? | Syngene International's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Syngene International? | Current EBITDA multiple of Syngene International is 23.7x. |
| What is the current FCF of Syngene International? | Syngene International's last 12 months FCF is $31.9M. |
| What is Syngene International's FCF margin? | Syngene International's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Syngene International? | Current FCF multiple of Syngene International is 87.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
